Total Payments
$605,590
2024 Payments
$55,344
Companies
76
Transactions
1,309
Medicare Patients
985
Medicare Billing
$98,688
Payment Breakdown by Category
Other$374,805 (61.9%)
Travel$139,258 (23.0%)
Consulting$67,567 (11.2%)
Food & Beverage$23,370 (3.9%)
Education$590.39 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $374,420 | 150 | 61.8% |
| Travel and Lodging | $139,258 | 343 | 23.0% |
| Consulting Fee | $67,567 | 30 | 11.2% |
| Food and Beverage | $23,370 | 771 | 3.9% |
| Education | $590.39 | 14 | 0.1% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $385.00 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $154,746 | 145 | $0 (2024) |
| Pharmacyclics LLC, An AbbVie Company | $145,032 | 259 | $0 (2023) |
| Janssen Biotech, Inc. | $127,641 | 218 | $0 (2024) |
| Celgene Corporation | $56,759 | 118 | $0 (2024) |
| Gilead Sciences, Inc. | $41,321 | 61 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $17,700 | 55 | $0 (2024) |
| GENZYME CORPORATION | $13,139 | 19 | $0 (2024) |
| GlaxoSmithKline, LLC. | $8,940 | 10 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $6,973 | 19 | $0 (2020) |
| Incyte Corporation | $3,916 | 19 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $55,344 | 152 | Janssen Biotech, Inc. ($34,647) |
| 2023 | $30,616 | 80 | Janssen Biotech, Inc. ($13,729) |
| 2022 | $59,774 | 124 | Janssen Biotech, Inc. ($28,527) |
| 2021 | $39,119 | 91 | Pharmacyclics LLC, An AbbVie Company ($15,265) |
| 2020 | $12,950 | 40 | Pharmacyclics LLC, An AbbVie Company ($7,713) |
| 2019 | $75,680 | 220 | Janssen Biotech, Inc. ($26,529) |
| 2018 | $154,747 | 297 | Janssen Scientific Affairs, LLC ($50,127) |
| 2017 | $177,360 | 305 | Janssen Scientific Affairs, LLC ($103,143) |
All Payment Transactions
1,309 individual payment records from CMS Open Payments — Page 1 of 53
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $281.40 | General |
| Category: Oncology | ||||||
| 12/25/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | Cash or cash equivalent | $59.03 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $145.25 | General |
| Category: Oncology | ||||||
| 12/09/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $14.91 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 12/06/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $121.39 | General |
| Category: Hematology | ||||||
| 12/06/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $67.28 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 11/25/2024 | Deciphera Pharmaceuticals Inc. | QINLOCK (Drug) | Food and Beverage | In-kind items and services | $48.79 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | — | Food and Beverage | In-kind items and services | $101.96 | General |
| 11/13/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $8.36 | General |
| Category: Iron Deficiency Anemia | ||||||
| 11/12/2024 | Lilly USA, LLC | VERZENIO (Drug), RETEVMO, JAYPIRCA | Food and Beverage | In-kind items and services | $17.83 | General |
| Category: Oncology | ||||||
| 11/06/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $85.84 | General |
| Category: Oncology | ||||||
| 11/05/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Education | In-kind items and services | $25.95 | General |
| Category: Oncology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 11/01/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Oncology | ||||||
| 10/30/2024 | BeiGene USA, Inc. | BRUKINSA (Drug) | Food and Beverage | In-kind items and services | $7.42 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,125.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Food and Beverage | In-kind items and services | $22.48 | General |
| Category: Rare Disease | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | Cash or cash equivalent | $546.72 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Travel and Lodging | In-kind items and services | $218.07 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | Cash or cash equivalent | $56.10 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | Cash or cash equivalent | $16.56 | General |
| Category: Oncology | ||||||
| 10/23/2024 | Janssen Biotech, Inc. | DARZALEX (Biological), TECVAYLI | Food and Beverage | Cash or cash equivalent | $5.90 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 223 | 394 | $93,299 | $27,157 |
| 2022 | 4 | 220 | 450 | $76,022 | $21,846 |
| 2021 | 4 | 210 | 387 | $81,581 | $25,788 |
| 2020 | 7 | 332 | 514 | $95,353 | $23,897 |
Total Patients
985
Total Services
1,745
Medicare Billing
$98,688
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 79 | 206 | $46,432 | $14,745 | 31.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 59 | 88 | $13,566 | $3,344 | 24.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 25 | $9,766 | $2,204 | 22.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 17 | 19 | $5,671 | $1,999 | 35.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 13 | 13 | $5,155 | $1,814 | 35.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 20 | 20 | $6,197 | $1,563 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 23 | $6,512 | $1,487 | 22.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 101 | 290 | $43,632 | $13,152 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 32 | 32 | $9,728 | $2,954 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 25 | 38 | $10,716 | $2,065 | 19.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 19 | 24 | $5,280 | $1,850 | 35.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 43 | 66 | $6,666 | $1,825 | 27.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 73 | 181 | $38,785 | $13,239 | 34.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 64 | 117 | $17,100 | $5,560 | 32.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 21 | 33 | $12,291 | $3,310 | 26.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 24 | 24 | $7,080 | $2,471 | 34.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 16 | 18 | $4,955 | $893.48 | 18.0% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 12 | 14 | $1,370 | $314.16 | 22.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 112 | 241 | $34,831 | $9,132 | 26.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 51 | 75 | $15,825 | $4,655 | 29.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 43 | 64 | $17,344 | $3,547 | 20.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 13 | 13 | $4,888 | $1,616 | 33.1% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 12 | 14 | $5,138 | $1,140 | 22.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 12 | $3,252 | $981.61 | 30.2% |
| 99203 | New patient office or other outpatient visit, typically 30 minutes | Facility | 2020 | 15 | 15 | $3,360 | $837.08 | 24.9% |
About Dr. Bipinkumar Amin, MD
Dr. Bipinkumar Amin, MD is a Hematology & Oncology healthcare provider based in Watertown, South Dakota. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1568415628.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bipinkumar Amin, MD has received a total of $605,590 in payments from pharmaceutical and medical device companies, with $55,344 received in 2024. These payments were reported across 1,309 transactions from 76 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($374,420).
As a Medicare-enrolled provider, Amin has provided services to 985 Medicare beneficiaries, totaling 1,745 services with total Medicare billing of $98,688. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Watertown, SD
- Active Since 05/18/2006
- Last Updated 06/21/2016
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1568415628
Products in Payments
- DARZALEX (Biological) $228,564
- Imbruvica (Drug) $97,336
- IMBRUVICA (Drug) $83,085
- Revlimid (Drug) $54,501
- Zydelig (Drug) $36,654
- TECVAYLI (Biological) $15,495
- SARCLISA (Biological) $11,930
- ONIVYDE (Drug) $6,170
- TAGRISSO (Drug) $6,159
- CALQUENCE (Drug) $5,476
- LYNPARZA (Drug) $4,030
- PADCEV (Biological) $3,213
- PADCEV (Drug) $2,874
- BRUKINSA (Drug) $2,759
- XPOVIO (Drug) $2,299
- IMFINZI (Drug) $1,587
- Adcetris (Biological) $1,572
- Cabometyx (Drug) $1,524
- CABOMETYX (Drug) $1,470
- Yescarta (Drug) $1,386
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.